Evidence map›Paper›PMID 39602497›Full record

ArticleThe Journal of infectious diseases2025

Comprehensive Assessment of Initial Adaptation of Extended-Spectrum β-Lactamase-Positive ST131 Escherichia coli to Carbapenem Exposure.

William C Shropshire, Xinhao Song, Jordan Bremer, Seokju Seo, Susana Rodriguez, Selvalakshmi Selvaraj Anand, An Q Dinh, Micah M Bhatti, Anna Konovalova, Cesar A Arias and 3 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

William C ShropshireDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center.ORCID 0000-0001-8556-3248
Xinhao SongDepartment of Biosciences, Rice University.ORCID 0009-0009-4776-2428
Jordan BremerDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center.
Seokju SeoDepartment of Biosciences, Rice University.ORCID 0000-0003-1699-6271
Susana RodriguezDepartment of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center at Houston.ORCID 0000-0002-7136-3728
Selvalakshmi Selvaraj AnandProgram in Diagnostic Genetics and Genomics, The University of Texas MD Anderson Cancer Center School of Health Professions.
An Q DinhDivision of Infectious Diseases and Center for Infectious Diseases Research, Houston Methodist Hospital and Houston Methodist Research Institute.
Micah M BhattiDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston.ORCID 0000-0001-5857-5825
Anna KonovalovaDepartment of Microbiology and Molecular Genetics, McGovern Medical School, The University of Texas Health Science Center at Houston.ORCID 0000-0002-2238-8849
Cesar A AriasDivision of Infectious Diseases and Center for Infectious Diseases Research, Houston Methodist Hospital and Houston Methodist Research Institute.
Awdhesh KaliaProgram in Diagnostic Genetics and Genomics, The University of Texas MD Anderson Cancer Center School of Health Professions.ORCID 0000-0001-5365-1702
Yousif ShamooDepartment of Biosciences, Rice University.ORCID 0000-0001-9241-8962
Samuel A ShelburneDepartment of Infectious Diseases and Infection Control, The University of Texas MD Anderson Cancer Center.ORCID 0000-0001-9721-263X

Funding

Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
Biogenesis of Surface-Exposed Lipoproteins in Gram-Negative BacteriaR01GM133904 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KONOVALOVA, ANNA · 2019 to 2023
$1.6M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
National Institute of Allergy and Infectious DiseasesNIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI148342NIAID NIH HHS T32 AI141349NIGMS NIH HHS R01 GM133904NIH HHS K24AI121296
6 · The paper itself

Abstract

backgroundIt remains unclear how high-risk Escherichia coli lineages, like sequence type (ST) 131, initially adapt to carbapenem exposure in their progression to carbapenem resistance.

methodsCarbapenem mutation frequency was measured in multiple subclades of extended-spectrum β-lactamase (ESBL)-positive ST131 clinical isolates using a fluctuation assay followed by whole genome sequencing (WGS) characterization. Genomic, transcriptomic, and porin analyses of the ST131 C2/H30Rx isolate MB1860, under prolonged, increasing carbapenem exposure was performed using 2 experimental evolutionary platforms to measure fast versus slow adaptation.

resultsAll 13 ESBL-positive ST131 strains selected from a diverse (n = 184) ST131 bacteremia cohort had detectable ertapenem (ETP) mutational frequencies, with a positive correlation between initial ESBL gene copy number and mutation frequency (r = 0.87, P < 1e-5). WGS analysis of mutants showed that initial response to ETP exposure resulted in significant increases in ESBL gene copy numbers or mutations in Omp genes in the absence of ESBL gene amplification with subclade-specific associations. In both experimental evolutionary platforms, MB1860 responded to initial ETP exposure by increasing blaCTX-M-15 copy numbers via modular, IS26-mediated pseudocompound transposons (PCTns). Increased transcript level of genes present within the PCTn was a conserved expression signal in both experimental evolutionary platforms. Stable mutations in Omp encoding genes were detected only after prolonged increasing carbapenem exposure, consistent with clinical observations.

conclusionsESBL gene amplification is a conserved response to initial carbapenem exposure, especially within the high-risk ST131 C2/H30Rx subclade. Targeting such amplification could assist with mitigating carbapenem resistance development.

Indexed as

Anti-Bacterial Agentsbeta-LactamasesCarbapenemsEscherichia coliErtapenemEscherichia coli InfectionsGenome, BacterialHumansMicrobial Sensitivity TestsMutationMutation RatePorinsWhole Genome SequencingAnti-Bacterial Agentsbeta-LactamasesCarbapenemsErtapenemPorinsESBL gene amplificationexperimental evolutionnon-carbapenemase carbapenem resistancepseudo compound transposonsequence type 131

Identifiers

PMID39602497
PMCPMC11998557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.